Influenza vaccine trivalent - Seqirus
Alternative Names: Afluria; Enzira; Fluvax; Inactivated Influenza Vaccine; NilgripLatest Information Update: 30 Dec 2021
Price :
$50 *
At a glance
- Originator CSL
- Developer Seqirus
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 04 Oct 2018 Registered for Influenza virus infections (In children, In infants, Prevention) in USA (IM)
- 05 Jul 2016 Seqirus plans an Enhanced Passive Safety Surveillance clinical trial for Influenza virus infections (Prevention) in United Kingdom (IM) (UKCRN30538)
- 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus